Drug Discovery AI Talk

Dr. Jake Chen
  • 0,0 (0)
  • Neues aus der Technik
  • Wöchentlich

Late-breaking advances in AI-enabled drug discovery, including news, research progress, market trends, and interviews

  1. vor 2 Std.

    #69. CollaboFest

    What if we could turn a spark of biological insight into a real-world, life-saving treatment? That is the core mission of CollaboFest, an innovative initiative designed to break down the slow, traditional bottlenecks of drug discovery. Organized by the University of Alabama at Birmingham's Systems Pharmacology AI Research Center (SPARC), alongside Southern Research, this unique program unites multidisciplinary teams from across the region. Together, these experts bridge the crucial gap between cutting-edge artificial intelligence and vital wet-lab validation. By combining powerful computational models with hands-on biological testing, CollaboFest dramatically accelerates the discovery of disease targets and the design of therapeutic molecules. It is about building a collaborative future where computer-generated predictions quickly become testable, life-saving therapies. For more information, visit smartdrugdiscovery.org. Produced by Dr. Jake Chen.

    #69. CollaboFest

  2. 31. Juli

    #68. Molecular Glues in Therapy

    In this episode, we explore the rapid evolution of molecular glues, a breakthrough in targeted protein degradation that stabilizes protein interactions to treat previously incurable diseases. Historically discovered by chance, this field is moving toward a systematic design approach by integrating artificial intelligence, functional genomics, and biased chemical libraries. Current research emphasizes using machine learning to predict complex protein interfaces and utilizing covalent bonding to improve drug potency. Furthermore, a strategic partnership between Protina and Onconic Therapeutics highlights the commercial push to apply these AI-driven platforms to develop next-generation cancer therapies. Collectively, the texts illustrate how the fusion of computational modeling and synthetic biology is transforming "serendipitous" discoveries into a programmable era of pharmacology. Produced by Dr. Jake Chen.

    #68. Molecular Glues in Therapy

  3. 24. Juli

    #67. Does Size Matter?

    In this episode, we examine whether increasing the size and depth of neural networks truly enhances molecular property prediction compared to traditional machine learning. A recent study reveals that classical models using chemical fingerprints often outperform or match deep learning architectures, particularly when dealing with limited datasets or local structural variations. While foundation models and graph neural networks show promise when there is a significant difference between training and testing data, they are frequently hindered by activity cliffs and label noise. Ultimately, the evidence suggests that model scale is not a guaranteed predictor of success, and sophisticated models should always be measured against strong classical baselines. Therefore, practitioners are advised to select the simplest effective model that aligns with their specific chemical data and deployment goals. Produced by Dr. Jake Chen.

    #67. Does Size Matter?

  4. 17. Juli

    #66. Quantitative Systems Pharmacology

    In this episode, we explore the evolving role of Quantitative Systems Pharmacology (QSP) in drug development, particularly as a mechanistic alternative to traditional animal testing. It details how mathematical modeling can integrate human-relevant data and biological pathways to better predict drug safety and efficacy before clinical trials. The sources highlight recent 2026 FDA draft guidances that establish a regulatory framework for using these models to select initial human doses. While the text acknowledges that QSP is not yet a total replacement for animal studies, it proposes a staged roadmap for its integration. This strategy emphasizes combining computational models with New Approach Methodologies (NAMs), such as organoids, to improve translatability. Ultimately, the documentation serves as a guide for achieving regulatory-grade validation and shifting toward more ethical, human-centric pharmacology. Produced by Dr. Jake Chen.

    #66. Quantitative Systems Pharmacology

  5. 10. Juli

    #65. Orbiting around Big Pharma

    In this episode, we explore Lilly TuneLab as a major signal of where AI drug discovery may be heading: toward powerful platform ecosystems that combine proprietary pharmaceutical data, advanced predictive models, federated learning, and large-scale compute. On the positive side, platforms like TuneLab could help biotech companies derisk drug assets earlier, improve safety and pharmacokinetic predictions, reduce wasted experiments, and give smaller teams access to capabilities once reserved for Big Pharma. At the same time, this new model raises important questions about scientific independence, hidden bias, IP protection, and whether corporate AI platforms could become soft gatekeepers for what counts as a promising drug candidate. The best path forward is not to reject these platforms, but to use them wisely: as acceleration and second-opinion tools, complemented by open benchmarks, independent validation, human-relevant disease models, transparent governance, and mechanism-aware scientific judgment. Produced by Dr. Jake Chen.

    #65. Orbiting around Big Pharma

  6. 3. Juli

    #64. Foundation Models

    In this episode, we explore the surge of foundation models (FMs) within pharmaceutical research, noting that over 200 such models were published by early 2025. Unlike traditional task-specific AI, these versatile algorithms are pre-trained on massive datasets to identify broad biological patterns before being refined for specialized functions. We detail how FMs are currently applied to transcriptomics, protein structures, and pathology imaging to enhance the speed and efficiency of drug discovery. Despite hurdles like data scarcity and technical "hallucinations," the source envisions a future where automated workflows use these models to identify drug targets and design molecules. This transition suggests a shift toward a "lab-in-the-loop" paradigm, where AI predictions and experimental results continuously optimize one another. Ultimately, the text argues that FMs possess transformative potential to modernize the historically slow and expensive process of creating new medicines. Produced by Dr. Jake Chen.

    #64. Foundation Models

  7. 26. Juni

    #63. The Era of NAMs

    This podcast explores the transformative shift toward New Approach Methodologies (NAMs), which utilize human-relevant experimental and computational systems to modernize drug discovery and biomedical research. Major federal initiatives from the NIH and FDA are establishing a robust infrastructure for these technologies, moving them from peripheral alternatives to central organizing principles in regulatory science. The sources highlight how AI-driven integration of in vitro assays, such as organoids and tissue chips, with in silico modeling can significantly enhance the accuracy of safety and efficacy predictions. A featured case study on liver injury demonstrates that combining deep learning with human cell data provides more reliable results than traditional animal testing. Ultimately, the transition focuses on creating evidence-based ecosystems in which the choice of model is determined by its scientific fitness for a specific context of use. Growing policy alignment and FAIR data standards are currently paving the way for a faster, more ethical, and clinically predictive translational corridor. Produced by Dr. Jake Chen.

    #63. The Era of NAMs

  8. 19. Juni

    #62. Predicting Toxicity

    In this episode, we investigate the significant evolution of AI-driven toxicity prediction, detailing how the field has shifted from simple statistical models to sophisticated deep learning and multimodal systems. It highlights a variety of computational tools, distinguishing between modern machine learning platforms like ProTox 3.0 and established regulatory-facing frameworks such as the OECD QSAR Toolbox. We emphasize that while these technologies accelerate drug discovery and chemical safety assessments, their reliability varies greatly depending on the specific biological endpoint and data quality. Furthermore, we advocate for a rigorous validation workflow that combines structural analysis with biological response data and expert human judgment. Ultimately, we explore the field's future, noting the emerging role of large language models and the ongoing challenge of translating in silico results into human-relevant safety outcomes. Produced by Dr. Jake Chen.

    #62. Predicting Toxicity
Alle anzeigen (69)

Info

Late-breaking advances in AI-enabled drug discovery, including news, research progress, market trends, and interviews

Informationen

  • Erstellt von
    Dr. Jake Chen
  • Jahre aktiv
    2025 - 2026
  • Folgen
    69
  • Bewertung
    Unbedenklich
  • Copyright
    © Dr. Jake Chen
  • Sendungswebsite
    Drug Discovery AI Talk

Das gefällt dir vielleicht auch